KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Non-Current Deferred Tax Liability (2022 - 2025)

Historic Non-Current Deferred Tax Liability for Halozyme Therapeutics (HALO) over the last 3 years, with Q4 2025 value amounting to $231.9 million.

  • Halozyme Therapeutics' Non-Current Deferred Tax Liability rose 13097.46% to $231.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $231.9 million, marking a year-over-year increase of 13097.46%. This contributed to the annual value of $231.9 million for FY2025, which is 13097.46% up from last year.
  • According to the latest figures from Q4 2025, Halozyme Therapeutics' Non-Current Deferred Tax Liability is $231.9 million, which was up 13097.46% from $8.2 million recorded in Q3 2025.
  • In the past 5 years, Halozyme Therapeutics' Non-Current Deferred Tax Liability registered a high of $231.9 million during Q4 2025, and its lowest value of $3.3 million during Q2 2022.
  • Its 3-year average for Non-Current Deferred Tax Liability is $56.9 million, with a median of $13.6 million in 2024.
  • Data for Halozyme Therapeutics' Non-Current Deferred Tax Liability shows a peak YoY increase of 13097.46% (in 2025) and a maximum YoY decrease of 3124.16% (in 2025) over the last 5 years.
  • Halozyme Therapeutics' Non-Current Deferred Tax Liability (Quarter) stood at $29.0 million in 2022, then skyrocketed by 246.36% to $100.4 million in 2024, then skyrocketed by 130.97% to $231.9 million in 2025.
  • Its last three reported values are $231.9 million in Q4 2025, $8.2 million for Q3 2025, and $100.4 million during Q4 2024.